EUVIMEDEUVIMED entdecken
Open Access

Clinical Management of Ovarian Function Suppression in Premenopausal Women With Breast Cancer: A Survey of Members of ASCO

Catherine M Kelly iD, Kathleen E Bennett iD, Caitriona Cahir, Andrea Eisen, Lajos Pusztai iD

JCO Oncology Practice · 2025-05 · 21 (5) · 654-662

DOI: 10.1200/op-24-00502 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Practice, 2025-05. Verfasst von Catherine M Kelly und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Mater Private Hospital, Dublin, Ireland. Hauptthemen laut MEDLINE: Breast Neoplasms, Ovary, Gonadotropin-Releasing Hormone, Antineoplastic Agents, Hormonal. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Ovarian function suppression (OFS) with gonadotropin-releasing hormone agonists (GnRHas) is a standard of care for premenopausal patients with high-risk stage II/III hormone receptor–positive breast cancer (BC). Practical guidance on the optimal choice of GnRHa, timing, schedule, and monitoring is limited. Our aim was to determine how oncologists use OFS in routine care. METHODS We designed a questionnaire to determine the choice of GnRHa, schedule, duration, initiation, use of bone modifiers, and monitoring of estradiol (E2). The questionnaire was sent to oncologists treating BC, in practice for >1 year and participating in the ASCO Research Survey Pool (RSP). It was also forwarded by investigators to oncologists meeting these criteria. The survey was open between November 14, 2023, and January 5, 2024. RESULTS Of 996 oncologists participating in the ASCO RSP, 178 (18%) completed the survey. An additional 56 oncologists contacted by investigators responded. Respondents were from the United States (57%), Asia (15%), and Europe (14%). Goserelin (54%) and leuprolide (39%) were the most frequently used GnRHas and were administered once every month by 46%. Approaches to starting GnRHas were varied. Most continued them for the duration of aromatase inhibitor therapy (57%). Estradiol monitoring was performed regularly, sometimes, or never by 43%, 27%, and 27%, respectively. The E2 assays used were standard (65%), ultrasensitive (16%), and unknown (14%). Interpreting E2 assay results were considered difficult by 55%; however, 62% of oncologists changed treatment on the basis of them. A total of 92% of respondents would like ASCO guidance on the practical use of OFS. CONCLUSION Considerable practice variation exists for similar clinical scenarios in OFS administration. Respondents would welcome ASCO guidance on all aspects of OFS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsOvaryGonadotropin-Releasing HormoneAntineoplastic Agents, HormonalHumansFemalePremenopauseSurveys and QuestionnairesAdultMiddle Aged

Substanzen

Gonadotropin-Releasing HormoneAntineoplastic Agents, Hormonal

Autor:innen und Institutionen

  • Department of Medical Oncology, Mater Private Hospital, Dublin, Ireland.
  • School of Population Health, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
  • Odette Cancer Center, Sunnybrook Health Sciences Centre, Toronto, Canada.
  • Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada.
  • Center for Breast Cancer, Smilow Cancer Hospital, Yale, New Haven, CT.

ORCID-Profile: Catherine M Kelly, Kathleen E Bennett, Lajos Pusztai

Zitieren

APA

Kelly, C. M., Bennett, K. E., Cahir, C., Eisen, A., & Pusztai, L. (2025). Clinical Management of Ovarian Function Suppression in Premenopausal Women With Breast Cancer: A Survey of Members of ASCO. JCO Oncology Practice, 21(5), 654-662. https://doi.org/10.1200/op-24-00502

Vancouver

Kelly CM, Bennett KE, Cahir C, Eisen A, Pusztai L. Clinical Management of Ovarian Function Suppression in Premenopausal Women With Breast Cancer: A Survey of Members of ASCO. JCO Oncology Practice. 2025;21(5):654-662. doi:10.1200/op-24-00502

BibTeX
@article{Kelly2025,
  author = {Kelly, Catherine M and Bennett, Kathleen E and Cahir, Caitriona and Eisen, Andrea and Pusztai, Lajos},
  title = {Clinical Management of Ovarian Function Suppression in Premenopausal Women With Breast Cancer: A Survey of Members of ASCO},
  journal = {JCO Oncology Practice},
  year = {2025},
  volume = {21},
  number = {5},
  pages = {654--662},
  doi = {10.1200/op-24-00502}
}
Kostenlos starten →